Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Gabe Fernandez who wrote (203)	11/12/1998 10:18:00 PM
From: Cacaito	Respond to of 1386

Gabe Fernandez, Dexanabinol phase II study is ready for a more niche type of journal ( Neurosurgery, ER, Trauma, Critical Care). A good phase III study will be disputed among the most prestigious journals, but plenty of time before that happens. I will like to see the study in a good journal to see the details and better analyze the success chances of Dexanabinol, and the peer review critics. Then I will probably invest more on PARS. Right now, I am counting on Alrex/Lotemax and Dexanabinol is just a bonus.